(Q42999273)

12 November 2017

Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis (English)

1 reference

12 November 2017

1 reference

1 reference

Cristina M Rocha

1

1 reference

12 November 2017

Renata M Perez

2

1 reference

12 November 2017

Adalgisa P Ferreira

3

1 reference

12 November 2017

Roberto J Carvalho-Filho

4

1 reference

12 November 2017

Fabio H Pace

5

1 reference

12 November 2017

Ivonete S Silva

6

1 reference

12 November 2017

José O M Pestana

7

1 reference

12 November 2017

Valeria P Lanzoni

8

1 reference

12 November 2017

Antonio E Silva

9

1 reference

12 November 2017

Maria Lucia G Ferraz

10

1 reference

12 November 2017

1 April 2006

1 reference

12 November 2017

1 reference

12 November 2017

26

1 reference

12 November 2017

305-310

1 reference

12 November 2017

3

1 reference

Management of chronic viral hepatitis before and after renal transplantation

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Hepatitis C infection and the patient with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Impact of hepatitis B and C virus on kidney transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Histopathological features of hepatitis C in renal transplant candidates [see comment]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

The tolerance and efficacy of interferon‐α in haemodialysis patients with HCV infection: a multicentre, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01225.X

10.1111/J.1478-3231.2005.01225.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference